Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Neurological and psychiatric adverse effects of antiretroviral drugs.

Abers MS, Shandera WX, Kass JS.

CNS Drugs. 2014 Feb;28(2):131-45. doi: 10.1007/s40263-013-0132-4. Review.

PMID:
24362768
2.

Peripheral neuropathy and antiretroviral drugs.

Dalakas MC.

J Peripher Nerv Syst. 2001 Mar;6(1):14-20. Review.

PMID:
11293802
3.

Understanding and avoiding antiretroviral adverse events.

Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD.

Curr Pharm Des. 2006;12(9):1075-90. Review.

PMID:
16515487
4.
5.

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005481. doi: 10.1002/14651858.CD005481.pub3. Review.

PMID:
23543540
6.

[Characteristics of antiretroviral drugs].

Ribera E, Tuset M, Martín M, del Cacho E.

Enferm Infecc Microbiol Clin. 2011 May;29(5):362-91. doi: 10.1016/j.eimc.2011.02.004. Epub 2011 Apr 30. Review. Spanish.

PMID:
21531048
7.

Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF.

Curr Top Med Chem. 2004;4(9):895-919. Review.

PMID:
15134548
8.

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

Margolis DA, Brinson CC, Smith GH, de Vente J, Hagins DP, Eron JJ, Griffith SK, St Clair MH, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR; LAI116482 Study Team.

Lancet Infect Dis. 2015 Oct;15(10):1145-55. doi: 10.1016/S1473-3099(15)00152-8. Epub 2015 Jul 19.

PMID:
26201299
9.

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.

Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA.

AIDS. 2005 Sep 2;19(13):1341-9.

PMID:
16103764
10.

Abacavir: a review of its clinical potential in patients with HIV infection.

Hervey PS, Perry CM.

Drugs. 2000 Aug;60(2):447-79. Review.

PMID:
10983741
11.

An introduction to nucleoside and nucleotide analogues.

Squires KE.

Antivir Ther. 2001;6 Suppl 3:1-14. Review.

PMID:
11678469
12.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
13.

[Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs].

Sánchez Hellín V, Gutiérrez Rodero F.

Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 6:24-33. Review. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2008 Oct;26(8):536.

PMID:
18680693
14.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
15.

Antiretroviral drugs.

Warnke D, Barreto J, Temesgen Z.

J Clin Pharmacol. 2007 Dec;47(12):1570-9. Review.

PMID:
18048575
16.
17.

Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Kryst J, Kawalec P, Pilc A.

PLoS One. 2015 May 1;10(5):e0124279. doi: 10.1371/journal.pone.0124279. eCollection 2015. Review.

18.

Delavirdine: a review of its use in HIV infection.

Scott LJ, Perry CM.

Drugs. 2000 Dec;60(6):1411-44. Review.

PMID:
11152019
19.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
20.

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM.

Clin Pharmacokinet. 2010;49(1):17-45. doi: 10.2165/11318110-000000000-00000. Review.

PMID:
20000887

Supplemental Content

Support Center